Document Detail


Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
MedLine Citation:
PMID:  18585505     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Despite improvements in low-density lipoprotein cholesterol (LDL-C) levels, recent national data are limited regarding the proportion of adults at recommended lipid levels according to the presence of cardiovascular disease (CVD) and related comorbidities. We evaluated the proportion of US adults with and without these conditions at (and distance to) recommended levels of LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, and triglycerides. METHODS: We analyzed data from adults aged > or =20 who had fasted for 8 or more hours (n = 2,883, weighted to a US population of 128.5 million) in the National Health and Nutrition Examination Survey 2003-2004, a nationally representative cross-sectional survey. The number of adults at National Cholesterol Education Program recommended levels for LDL-C, non-HDL-C, HDL-C, triglycerides, and combined lipids, stratified by sex, age group, ethnicity, and the presence of CVD comorbidities was determined. RESULTS: Although 85% to 89% of persons without CVD or related comorbidities were at recommended levels for LDL-C, non-HDL-C, HDL-C, and triglycerides, only 36% to 37% of those with CVD or related comorbidities were at recommended levels for LDL-C and non-HDL-C, and only 17% were at recommended levels for all lipids. Treated persons compared with those untreated had significantly lower LDL-C (112.3 vs 156.7 mg/dL, P < .001) and non-HDL-C levels (145.9 vs 188.7 mg/dL, P < .001), but similar HDL-C (52.0 vs 50.1 mg/dL, P = .09) and triglyceride (160.1 vs 148.7 mg/dL, P = .20) levels. CONCLUSIONS: Despite improved LDL-C levels, many adults, especially with CVD or related comorbidities, are not at recommended levels for all lipids. Improved treatment efforts to target the spectrum of dyslipidemia are needed.
Authors:
Heli Ghandehari; Sachin Kamal-Bahl; Nathan D Wong
Related Documents :
7418145 - Plasma high-density lipoprotein cholesterol: association with measurements of body mass...
7161045 - Contributions of different lipoprotein fractions to variations in total cholesterol bet...
7881705 - Effect of bevantolol and propranolol on serum lipids in patients with essential hyperte...
7517835 - Efficacy and safety of fluvastatin, a new hmg coa reductase inhibitor, in elderly hyper...
21326875 - Increasing protein at the expense of carbohydrate in the diet down-regulates glucose ut...
22659245 - Histopathological changes in the livers of rabbit fish (siganus canaliculatus) followin...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-05-15
Journal Detail:
Title:  American heart journal     Volume:  156     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-30     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  112-9     Citation Subset:  AIM; IM    
Affiliation:
Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA 92697, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Distribution
Aged
Cardiovascular Diseases / diagnosis,  epidemiology*
Case-Control Studies
Cholesterol, HDL / standards*
Cholesterol, LDL / standards*
Comorbidity
Dyslipidemias / blood,  drug therapy,  epidemiology*
Female
Health Surveys
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Incidence
Male
Middle Aged
Prognosis
Reference Values
Risk Assessment
Sensitivity and Specificity
Severity of Illness Index
Sex Distribution
United States / epidemiology
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An assessment of the joint associations of aspirin and statin use with C-reactive protein concentrat...
Next Document:  Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutane...